Tyra Biosciences, Inc.
TYRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.35 | -0.27 | -0.06 | -0.12 |
| FCF Yield | -8.86% | -8.61% | -15.97% | -4.19% |
| EV / EBITDA | -8.25 | -6.78 | -1.19 | -10.79 |
| Quality | ||||
| ROIC | -29.78% | -37.92% | -21.13% | -8.61% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.73 | 0.91 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -38.36% | -0.13% | -108.33% | -202.24% |
| Safety | ||||
| Net Debt / EBITDA | 1.00 | 0.65 | 4.24 | 11.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -414.93 | -4,820.48 | -1,411.91 | -1,561.68 |